Please login to the form below

Not currently logged in
Email:
Password:

AZ's Faslodex recommended against in UK

The UK's National Institute for health and Clinical Excellence (NICE) has issued draft guidance recommending that AstraZeneca's breast cancer drug Faslodex not be used on the NHS

The UK's National Institute for health and Clinical Excellence (NICE) has issued draft guidance recommending that AstraZeneca's (AZ) breast cancer drug Faslodex (fulvestrant) not be used on the NHS.

The body, which regulates what treatments can be funded in England and Wales, claims that the drug does not represent a good use of NHS resources when used as an alternative to aromatase inhibitor therapy.

Faslodex is intended for use if anti-oestrogen treatments are no longer controlling the spread of the cancer in postmenopausal women who have locally advanced or metastatic breast cancer that is oestrogen-receptor-positive.

Commenting on the decision, Sir Andrew Dillon, chief executive of NICE, said: "After analysing the evidence comparing fulvestrant's clinical effectiveness with aromatase inhibitor therapy, our independent committee found that the estimates of overall survival and time to tumour progression were very uncertain."

There is now a consultation period until September 13, before a further review by an independent committee. Final guidance is expected in January 2012.

23rd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics